R&D News | pharmaphorum

News

RFK Jr defends HHS cuts, measles stance in Congress hearings

HHS Secretary Robert F Kennedy Jr would not explicitly endorse measles vaccines at Congressional hearings, and deflected questions on department cuts.

News

Novo makes fresh obesity play with $2.2bn Septerna deal

A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity.

News

GSK pays $1.2bn for liver drug as it culls TIGIT programme

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.

News

Digital support reduces GLP-1 dose needed for weight loss

Combining weight-loss drugs with online patient support can achieve results that match the drugs given on their own, but with a much-reduced dose.

News

Galapagos drops plan to split after 'market developments'

Shortly after announcing a plan to separate its drug and cell therapy businesses into two separate companies, Galapagos has had a change of heart.

News

Azafaros bags €132m for rare neuro-metabolic disorder drugs

Azafaros is set to start phase 3 trials of its lead drug for a trio of rare lysosomal storage disorders, backed by €132m in new Series B financing.

RFK Jr defends HHS cuts, measles stance in Congress hearings

Novo makes fresh obesity play with $2.2bn Septerna deal

GSK pays $1.2bn for liver drug as it culls TIGIT programme

Digital support reduces GLP-1 dose needed for weight loss

Galapagos drops plan to split after 'market developments'

Azafaros bags €132m for rare neuro-metabolic disorder drugs

Making direct-to-patient work, with Matt Wadyka

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks